Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:40 PM
Ignite Modification Date: 2025-12-25 @ 3:10 PM
NCT ID: NCT00473668
Description: None
Frequency Threshold: 5
Time Frame: Solicited local/general symptoms: during the 4-day post-vaccination period (Days 0-3); Unsolicited AEs: during the 31-day post-vaccination period (Days 0-30); SAEs: during the entire study period (Day 0 - Month 3).
Study: NCT00473668
Study Brief: Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Tritanrix-HepB/Hiberix Kft. Group Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age. 0 None 0 100 87 100 View
Tritanrix-HepB/Hiberix LD Group Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age. 0 None 0 100 84 100 View
Tritanrix-HepB/Hiberix HD Group Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age. 0 None 0 99 81 99 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View
Redness (mm) SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View
Drowsiness SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View
Fever (Axillary) SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View
Irritability SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View
Loss of appetite SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View
Swelling (mm) SYSTEMATIC_ASSESSMENT General disorders MedDRA 11.1 View